The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Ivosidenib and venetoclax +/- azacitidine for IDH1-mutated hematologic malignancies
Curtis Lachowiez, MD, MD Anderson Cancer Center, Houston, TX, gives an update on a clinical trial (NCT03471260) investigating ivosidenib and venetoclax with or without azacitidine to treat isocitrate dehydrogenase 1 (IDH1) mutated hematologic malignancies. There are four patient cohorts in the trial; two with a doublet combination of ivosidenib and venetoclax and two with a triplet combination of ivosidenib, venetoclax, and azacitidine. Data from the first three cohorts indicates that the doublet and triplet combinations are tolerable and effective. Adverse effects included IDH differentiation syndrome and tumor lysis syndrome, however patients were able to continue on the trial after treatment. The one-year overall survival in the three cohorts ranged from 50% to 83% and the 800mg dose of venetoclax cohort achieved a composite complete response rate of 100%. It should be noted that the cohorts were heterogenous, which could have affected response rates. Dr Lachowiez also discusses future directions for this trial. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
